This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Atreca Management

Management Kriterienprüfungen 3/4

Atreca CEO ist John Orwin , ernannt in Apr 2018, hat eine Amtszeit von 6.17 Jahren. Die jährliche Gesamtvergütung beträgt $927.03K , bestehend aus 64.8% Gehalt und 35.2% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.2% der Aktien des Unternehmens, im Wert von $6.98K . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 5 Jahre bzw. 5.5 Jahre.

Wichtige Informationen

John Orwin

Geschäftsführender

US$927.0k

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	64.8%
Amtszeit als Geschäftsführer	6.2yrs
Eigentum des Geschäftsführers	0.2%
Durchschnittliche Amtszeit des Managements	5yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	5.5yrs

Jüngste Management Updates

Recent updates

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von John Orwin im Vergleich zu den Einnahmen von Atreca verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Sep 30 2023	n/a	n/a	-US$98m
Jun 30 2023	n/a	n/a	-US$85m
Mar 31 2023	n/a	n/a	-US$93m
Dec 31 2022	US$927k	US$601k	-US$97m
Sep 30 2022	n/a	n/a	-US$105m
Jun 30 2022	n/a	n/a	-US$110m
Mar 31 2022	n/a	n/a	-US$108m
Dec 31 2021	US$4m	US$583k	-US$109m
Sep 30 2021	n/a	n/a	-US$103m
Jun 30 2021	n/a	n/a	-US$98m
Mar 31 2021	n/a	n/a	-US$92m
Dec 31 2020	US$5m	US$567k	-US$86m
Sep 30 2020	n/a	n/a	-US$83m
Jun 30 2020	n/a	n/a	-US$76m
Mar 31 2020	n/a	n/a	-US$74m
Dec 31 2019	US$845k	US$507k	-US$67m
Sep 30 2019	n/a	n/a	-US$59m
Jun 30 2019	n/a	n/a	-US$53m
Mar 31 2019	n/a	n/a	-US$44m
Dec 31 2018	US$5m	US$319k	-US$38m

Vergütung im Vergleich zum Markt: JohnDie Gesamtvergütung ($USD927.03K) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD649.63K).

Entschädigung vs. Einkommen: JohnDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

John Orwin (59 yo)

6.2yrs

Amtszeit

US$927,033

Vergütung

Mr. John A. Orwin, M.B.A. serves as Chairman of the Board for Nested Therapeutics since February 2024. He serves as Independent Chairman of the Board of AnaptysBio, Inc. since September 15, 2023. He has be...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
John Orwin	President	6.2yrs	US$927.03k	0.20% $ 7.0k
Tito Serafini	Founder & Director	no data	US$665.50k	0.81% $ 29.0k
Rick Ruiz	Principal Accounting Officer	less than a year	keine Daten	keine Daten
Courtney Phillips	General Counsel & Corporate Secretary	5yrs	keine Daten	0.073% $ 2.6k
Roger Ruiz	Vice President of Finance	no data	keine Daten	0.067% $ 2.4k

5.0yrs

Durchschnittliche Betriebszugehörigkeit

59.5yo

Durchschnittliches Alter

Erfahrenes Management: BCELDas Führungsteam des Unternehmens verfügt über eine langjährige Erfahrung (5 ).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
John Orwin	President	6.2yrs	US$927.03k	0.20% $ 7.0k
Tito Serafini	Founder & Director	14.4yrs	US$665.50k	0.81% $ 29.0k
Brian Atwood	Independent Chairman of the Board	10.5yrs	US$97.77k	0.13% $ 4.5k
Lawrence Steinman	Chairman of External Scientific Advisory Board & Technical Advisor	4.8yrs	US$150.00k	keine Daten
Kristine Ball	Independent Director	4.1yrs	US$64.27k	0% $ 0
William Robinson	Director	13.4yrs	US$312.77k	0.93% $ 33.2k
David Lacey	Independent Director	8.1yrs	US$70.77k	0% $ 0
Stephen Brady	Independent Director	2.9yrs	US$60.27k	0% $ 0
Douglas Crawford	Board Observer	no data	keine Daten	keine Daten
Andrew Farnum	Board Observer	no data	keine Daten	keine Daten
Lindsey Rolfe	Independent Director	4.8yrs	US$62.77k	0% $ 0
Stacey Ma	Independent Director	2.9yrs	US$57.77k	0% $ 0

5.5yrs

Durchschnittliche Betriebszugehörigkeit

57.5yo

Durchschnittliches Alter

Erfahrener Vorstand: BCELDie Vorstandsmitglieder gelten als erfahren (5.5 Jahre durchschnittliche Amtszeit).

This company listing is no longer active

Atreca Management

Management Kriterienprüfungen 3/4

Wichtige Informationen

Jüngste Management Updates

Atreca, Inc. Announces Resignation of Franklin Berger from the Board

Atreca, Inc. Announces Board Resignations

Insufficient new directors

Atreca, Inc. Announces Resignation of Herbert Cross, Chief Financial Officer

Insufficient new directors

Atreca, Inc. Announces the Appointment of Philippe Bishop, MD, as Chief Medical Officer

Recent updates

Atreca, Inc. Announces Resignation of Franklin Berger from the Board

Immunome, Inc. (NasdaqCM:IMNM) completed the acquisition of Substantially all Assets of Atreca, Inc. (NasdaqGS:BCEL).

Atreca, Inc. Files Form 15

Atreca, Inc.(OTCPK:BCEL) dropped from S&P TMI Index

Atreca, Inc.(OTCPK:BCEL) dropped from NASDAQ Composite Index

Atreca, Inc. Receives Written Notification from Nasdaq Regarding Minimum Bid Requirement

New major risk - Financial position

Atreca, Inc. Announces Board Resignations

Insufficient new directors

Atreca, Inc. Announces Resignation of Herbert Cross, Chief Financial Officer

Atreca Receives Notice from the Nasdaq Stock Market

Atreca, Inc. Reduces its Workforce by Approximately 40%

New major risk - Revenue and earnings growth

Here's Why We're A Bit Worried About Atreca's (NASDAQ:BCEL) Cash Burn Situation

Atreca, Inc. Presents Data from Ongoing Phase 1b Study of ATRC-101 in Patients with Select Advanced Solid Tumors During Oral Abstract

Insufficient new directors

Price target decreased by 24% to US$9.44

Atreca, Inc. Announces the Appointment of Philippe Bishop, MD, as Chief Medical Officer

Can Atreca (NASDAQ:BCEL) Afford To Invest In Growth?

Price target increased to US$15.57

Atreca GAAP EPS of -$0.72 misses by $0.02

Atreca, Inc.(NasdaqGS:BCEL) dropped from Russell 2500 Index

Here's Why We're A Bit Worried About Atreca's (NASDAQ:BCEL) Cash Burn Situation

Atreca Appoints Stephen Gould, Ph.D. as Chief Scientific Officer

Price target decreased to US$16.63

Atreca, Inc. Announces Publication in PNAS Mobilization of Innate and Adaptive Antitumor Immune Responses by the RNP-Targeting Antibody ATRC-101

Atreca: Biotech With Promise Based On First Candidate ATRC-101

Atreca, Inc. Provides an Update on Its Preclinical Pipeline in Oncology

Founder notifies of intention to sell stock

Is Atreca (NASDAQ:BCEL) In A Good Position To Invest In Growth?

Price target decreased to US$19.56

Atreca: Overvalued, Then Undervalued, Now Under Pressure - Making The Buy Case

Founder notifies of intention to sell stock

Atreca: Safety Data Brought Down Stock

Is Atreca (NASDAQ:BCEL) In A Good Position To Invest In Growth?

Price target decreased to US$25.33

Atreca, Inc.(NasdaqGS:BCEL) dropped from Russell 2500 Growth Index

We Think Atreca (NASDAQ:BCEL) Can Afford To Drive Business Growth

Chief Scientific Officer has left the company

Atreca, Inc Announces Executive Changes

Chief Business Officer has left the company

New 90-day low: US$13.00

Need To Know: Atreca, Inc. (NASDAQ:BCEL) Insiders Have Been Buying Shares

Co-Founder notifies of intention to sell stock

New 90-day high: US$15.82

We Think Atreca (NASDAQ:BCEL) Can Afford To Drive Business Growth

Atreca EPS misses by $0.06

Director notifies of intention to sell stock

New 90-day high: US$15.79

New 90-day low - US$12.67

Analysts update estimates

New 90-day low - US$14.63

Atreca, Inc. has completed a Follow-on Equity Offering in the amount of $125 million.

Analyse der Geschäftsführervergütung

Geschäftsführer

Amtszeit

Vergütung

Führungsteam

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter